Heterobifunctional CyTaC Molecules for Targeted Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for treating diseases such as cancer, inflammatory diseases, autoimmune diseases, viral infections, and bacterial infections face challenges including low bioavailability, high cost, thermal instability, and complex manufacturing processes associated with antibody-based therapeutics, while small molecule therapeutics often suffer from poor selectivity and off-target effects.
Innovation Solution
Development of heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs), which simultaneously bind to a target cell-surface protein and an exogenous antibody, utilizing a divalent linker to connect the target-binding moiety and the antibody-binding moiety, and specifically using an anti-cotinine antibody or its antigen-binding fragment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based therapeutics are used to target pathogenic cells, then selectivity and immune control are improved, but bioavailability, cost, thermal stability, and manufacturing complexity worsen
Solution Approach 1:
The patent divides the therapeutic agent into two distinct components: a small molecule warhead that provides the cytotoxic function and an antibody component that provides target recognition. These segments are connected via a linker, allowing each component to optimize its individual function while working together as a unified therapeutic system.
Solution Approach 2:
The patent creates a composite therapeutic agent by chemically conjugating a small molecule cytotoxic agent with an antibody through a linker. This composite structure combines the advantages of both components: the small molecule's potency and stability with the antibody's target specificity, while mitigating their individual disadvantages.
2Stability of the object's composition
If small molecule therapeutics are used to treat diseases, then affordability and stability are improved, but selectivity and off-target effects worsen
Solution Approach 1:
The patent merges the stable cytotoxic small molecule with the selective antibody through chemical conjugation. The resulting conjugate maintains the small molecule's stability and potency while acquiring the antibody's target-specific recognition capabilities, thereby combining the strengths of both therapeutic modalities.
Solution Approach 2:
The linker serves as an intermediary component that chemically connects the small molecule warhead to the antibody. This intermediary structure enables the stable small molecule to be delivered selectively to target cells via the antibody, bridging the gap between the stable but non-selective small molecule and the selective but less stable antibody.
3Reliability
If antibody-based therapeutics are used, then immune control and target specificity are improved, but bioavailability and thermal instability worsen
Solution Approach 1:
The patent changes the physical and chemical parameters of the therapeutic agent by transitioning from a pure antibody structure to a conjugate structure with a small molecule component. This parameter change enhances thermal stability and bioavailability while preserving the antibody's immune control capabilities through the maintained antibody portion of the conjugate.
Data Source
AI summary
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.